Ohio State opens canine pancreatitis trial for RABI-767

Ohio State University’s College of Veterinary Medicine and Lamassu Pets, the veterinary division of Lamassu Biotech, have launched an enrolling clinical trial of RABI-767 for dogs with acute pancreatitis, a condition both groups describe as painful, life-threatening, and still lacking an effective specific treatment in veterinary or human medicine. Ohio State said the NIH-supported study is testing a canine-specific version of the therapy, while the university’s trial listing describes a 14-day, placebo-controlled study in which dogs receive standard care plus either IVP/RABI-767 or placebo. The program is also positioned as a One Health effort, with company and federal grant materials saying canine data are intended to help refine dosing and support a phase 2 human development pathway. (vet.osu.edu)

Why it matters: For veterinary professionals, the significance is less about a product launch than about movement in a space that has long been dominated by supportive care. Ohio State’s trial page says enrolled dogs must have compatible clinical signs and ultrasound-confirmed pancreatitis, and that the study covers monitoring, recheck diagnostics, and up to $3,000 in hospitalization costs, which could make referral conversations easier for eligible pet parents. More broadly, recent review literature has underscored how limited the evidence base remains for canine acute pancreatitis management, even as the disease can carry substantial morbidity and mortality. (vmc.vet.osu.edu)

What to watch: Watch for enrollment progress, any clarification of the study design versus the university press release’s description of drug delivery, and whether Ohio State or Lamassu publishes interim efficacy or safety data that could shape both veterinary use and human trial planning. (vet.osu.edu)